AUSiMED's research into new treatments for Breast Cancer

Dr Shani Paluch-Shimon from Sheba Medical Centre talks about the need to carry out her research

If you are an Ashkenazi woman aged 20-40, you have a higher risk of developing "triple negative" aggressive breast cancer and current treatments may not always be effective as they aren’t specific for this cancer.

We urgently need $150,000 to fund medical research for young Ashkenazi women

We are fundraising to enable one year of collaborative research to be undertaken to enable our current funding of this project to continue. The research is described in more detail below.

How your support can help

$54 - one day of reagents used for research
$108 - one day’s work to prepare tissue samples for analysis
$540 - a day of research activities by Dr Shani Paluch-Shimon
$900 - one week of a researcher's time to carry out molecular analysis of samples

Donations are tax deductible - tax receipts will be issued by AUSiMED Ltd
First Name* Surname*
Preferred Phone*   Alternative Phone
Address Line 1* Address Line 2
City / Suburb* State Postcode*
Email* Country
Comments Donation $*
 Fields marked * must be completed
NOTE: Card details will be required
after the "Submit" button is clicked.
Transactions will appear on your bank statement as "AUSiMED Ltd"

Other Methods of Donating to AUSiMED:
  • By direct debit by calling AUSiMED on (03) 9272-5699
    to be provided with bank account details
  • Cheque by mail, made payable to AUSiMED Limited
    and posted to PO Box 2400 Caulfield VIC 3161.
  • Over the phone to AUSiMED. Phone (03) 9272 5699
  • For monthly workplace giving, AUSiMED is registered as a charity
    with a provider called "Good Company".
  • Ask your employer to register with Good Company to enable you
    to donate from your salary.


This research project we are supporting, is to help find a specific treatment for “triple negative” aggressive breast cancer, due to its increasing health risk for the Jewish community, in particular for young Ashkenazi women. This is because:

  • At least 1 in 40 Ashkenazi women have inherited a mutated BRCA 1 or 2 gene
    which greatly increases their risk of having breast cancer
  • This is a 20 times higher incidence than the rest of the community.
  • Ashkenazi women with these mutated genes are being diagnosed with breast cancer
    at progressively younger ages, and
  • Young Ashkenazi women, especially if they have an inherited BRCA1 gene, have a much higher risk of developing aggressive triple negative breast cancer. There are currently no targeted treatments for this type of cancer and as a result they have higher rates of mortality than for other breast cancers.

It is critical that these outcomes are improved for our vulnerable young women and AUSiMED is supporting a project to contribute to this goal

AUSiMED identified an outstanding collaboration of world leading teams consisting of, from Israel, Professor Bella Kaufman and Dr Shani Paluch-Shimon (originally from Melbourne) at Sheba Medical Centre together with a team from the Walter and Eliza Hall Institute (WEHI) in Melbourne. The Israeli team is analysing large numbers of blood and breast cancer samples collected from young women in Israel with triple negative breast cancer to identify biomarkers to help develop a new treatment and are also collaborating with WEHI.

We need your help to get this project moving FORWARD.

Help us SAVE women's lives, especially younger women.

DONATE NOW! Turn these triple negatives into a huge POSITIVE!

Funds raised will be used by Sheba Medical Centre in Israel to analyse at a molecular level, an initial group of previously collected breast cancer tissue to investigate how these cancer cells become resistant to treatment.

This research and the scientists involved are so impressive that the Melbourne team at WEHI have already received some Australian funding for this project from the National Breast Cancer Foundation to analyse the tissue samples they are collecting in Melbourne.

We believe that we have improved the chance of making a significant advance in understanding cancer resistance, because we have brought together an outstanding team of international scientists to work together. can also support this project.

Thank you for giving your valuable time to read about our project.